AI assistant
Flerie AB — Net Asset Value 2026
Mar 3, 2026
6601_rns_2026-03-03_b4fc07dd-f8ae-45df-ad65-091156d4da0d.pdf
Net Asset Value
Open in viewerOpens in your device viewer
Press Release
03 March 2026 08:00:00 CET
FLERIE
NET ASSET VALUE - 28 February 2026
On the 28 February 2026 Flerie AB's Net Asset Value (NAV) was SEK 3.281 million and NAV per share was SEK 42.36. Return on NAV per share in the month was -0.11%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
|---|---|---|---|---|
| Product Development | ||||
| Prokarium | 50% | 272 | 3.51 | 8.3% |
| Empros Pharma | 79% | 204 | 2.64 | 6.2% |
| Atrogi | 44% | 197 | 2.54 | 6.0% |
| KAHR Medical | 34% | 194 | 2.50 | 5.9% |
| Xspray Pharma | 18% | 192 | 2.48 | 5.9% |
| Bonsai Biotherapeutics | 100% | 156 | 2.01 | 4.7% |
| Lipum | 42% | 148 | 1.91 | 4.5% |
| Xintela | 60% | 141 | 1.82 | 4.3% |
| Microbiotica | 10% | 122 | 1.57 | 3.7% |
| AnaCardio | 13% | 79 | 1.02 | 2.4% |
| Mendus | 23% | 65 | 0.84 | 2.0% |
| Geneos Therapeutics | 15% | 65 | 0.83 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 53 | 0.68 | 1.6% |
| Vitara Biomedical | 11% | 51 | 0.66 | 1.6% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 1.0% |
| Egetis Therapeutics | 1% | 22 | 0.29 | 0.7% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
| Total | 2.013 | 25.99 | 61.4% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 6.2% |
| Symcel | 30% | 192 | 2.48 | 5.9% |
| Chromafora | 28% | 131 | 1.69 | 4.0% |
| Frontier Biosolutions | 2% | 26 | 0.33 | 0.8% |
| Nanologica | 44% | 15 | 0.19 | 0.5% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 565 | 7.30 | 17.2% | |
| Assets related to Portfolio companies | 236 | 3.04 | 7.2% | |
| Other assets and liabilities | 467 | 6.03 | 14.2% | |
| Net Asset Value | 3.281 | 42.36 | 100.0% |
Flerie AB
Skeppsbron 16
111 30 Stockholm
Press Release 03 March 2026 08:00:00 CET
FLERIE
For more information:
Ted Fjällman, CEO
Email: [email protected]
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Attachments
NET ASSET VALUE - 28 February 2026
Flerie AB | Skeppsbron 16 | 111 30 Stockholm